¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.
¼¼°èÀÇ ¿Ã¶õÀÚÇÉ ½ÃÀåÀº 2022³â¿¡ ¾à 18¾ï 4,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, ¿¹Ãø ±â°£ 2023³âºÎÅÍ 2030³â±îÁö 2.3% ÀÌ»óÀÇ °ß½ÇÇÑ ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.
¿Ã¶õÀÚÇÉÀº ÁÖ·Î Á¤½Å ºÐ¿Áõ°ú ¾ç±Ø¼º Àå¾Ö¿Í °°Àº ƯÁ¤ Á¤½Å ÁúȯÀÇ Ä¡·á¿¡ »ç¿ëµÇ´Â ¾à¹°ÀÔ´Ï´Ù. ºñÁ¤Çü Ç×Á¤½Åº´Á¦¶ó°í ÇÏ´Â ¾à¹° Ŭ·¡½º¿¡ ¼ÓÇÕ´Ï´Ù. ¿Ã¶õÀÚÇÉÀº µµÆĹΰú ¼¼·ÎÅä´Ñ°ú °°Àº ³úÀÇ Æ¯Á¤ ½Å°æ Àü´Þ ¹°ÁúÀÇ ¼öÁØ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â °ÍÀ¸·Î ÀÛ¿ëÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÈÇÐ ¹°ÁúÀº ±âºÐ, »ç°í, ÇൿÀ» Á¶ÀýÇÏ´Â ¿ªÇÒÀ» ´ã´çÇÕ´Ï´Ù. ¿Ã¶õÀÚÇÉ ½ÃÀåÀº ´Ù¾çÇÑ Áö¿ª¿¡¼ Á¤½ÅºÐ¿ÁõÀÇ À¯º´·ü »ó½Â, Á¤½ÅÀå¾Ö¿¡ ´ëÇÑ ½Ã¼³À» Á¦°øÇϱâ À§ÇÑ Á¤ºÎ À̴ϼÅƼºêÀÇ ±ÞÁõ, °¢Á¾ Á¤½ÅÀå¾Ö¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ ÀÇ½Ä Áõ°¡ µîÀÇ ¿äÀÎÀ¸·Î È®´ë ÀÖ½À´Ï´Ù.
¿Ã¶õÀÚÇÉ ½ÃÀåÀº ½Å°æ ÁúȯÀÇ ºóµµ°¡ Áõ°¡ÇÏ°í ¾ç±Ø¼º Àå¾Ö¿¡¼ ±Þ¼º Á¶º´ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¼¼°è Àα¸°¡ ¿¬°£ 1% ÀÌ»óÀÇ ¼Óµµ·Î Áõ°¡ÇÏ°í »ç¶÷µéÀÌ ÃæºÐÇÑ ´ºÆ®¸®³ë¸¦ ¹ÞÁö ¸øÇ߱⠶§¹®¿¡ Á¤½ÅºÐ¿Áõ°ú °°Àº Áúº´ÀÌ Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù. ¶óÀÌÇÁ ½ºÅ¸ÀÏÀÇ º¯È ¹× ÀÏ°ú »îÀÇ ½ºÆ®·¹½º Áõ°¡·Î ÀÎÇØ °¨Á¤Àû, Á¤½ÅÀû ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÏ°í ÀÖÀ¸¸ç, ÀÌ´Â ¿Ã¶õÀÚÇÉ ½ÃÀåÀÇ À¯¸®ÇÑ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹Ì±¹ ±¹¸³Á¤½ÅÀ§»ý¿¬±¸¼Ò(NIH)¿¡ µû¸£¸é ¹Ì±¹¿¡¼´Â 2020³â 5,290¸¸ ¸íÀÇ ¼ºÀÎÀÌ Á¤½ÅÁúȯÀ» °Þ¾ú½À´Ï´Ù. ±× °á°ú, Á¤½Å ÁúȯÀÇ Ä¡·á¿¡ ¿Ã¶õÀÚÇÉ Á¦Á¦ÀÇ »ç¿ëÀÌ ÇÊ¿äÇÑ Á¤½Å ÁúȯÀ» ¾Î°í ÀÖ´Â »ç¶÷ÀÌ Áõ°¡ÇÏ°í, ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ 2022³â ¼¼°èº¸°Ç±â±¸(WHO)ÀÇ µ¥ÀÌÅÍ¿¡ µû¸£¸é ¼¼°è¿¡¼´Â 8¸í Áß 1¸íÀÌ Á¤½ÅÁúȯÀ» ¾Î°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀϺΠÁö¿ª¿¡¼´Â ¿Ã¶õÀÚÇÉ ½Å¾à¿¡ ´ëÇÑ ÅõÀÚ¸¦ È®´ëÇÏ´Â À̴ϼÅƼºê°¡ °ÇØÁö°í ÀÖ½À´Ï´Ù. ÀÌ À̴ϼÅƼºê´Â ¿Ã¶õÀÚÇÉ ½ÃÀå¿¡ »õ·Î¿î °³Ã´ ±âȸ¸¦ Á¦°øÇÏ´Â °æÇâÀÌ ÀÖ½À´Ï´Ù. ±×·¯³ª ¿Ã¶õÀÚÇÉÀÇ ³ôÀº ºñ¿ë ¹× ±× ºÎÀÛ¿ëÀº 2023³âºÎÅÍ 2030³â±îÁöÀÇ ¿¹Ãø±â°£À» ÅëÇØ ¿Ã¶õÀÚÇÉ ½ÃÀåÀÇ È®´ë¸¦ ¹æÇØÇÒ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù.
¼¼°èÀÇ ¿Ã¶õÀÚÇÉ ½ÃÀå Á¶»ç¿¡¼ °í·ÁÇÑ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿, ¾ÆÇÁ¸®Ä« µîÀÔ´Ï´Ù. ºÏ¹Ì´Â ÀÌ Áö¿ªÀÇ Á¤½ÅºÐ¿Áõ µî Á¤½ÅÁúȯ À¯º´·ü »ó½Â, ³ôÀº º¸Çè º¸±Þ·ü ¹× ÀÇ·á½Ã¼³, µ¿Áö¿ª ÁÖ¿ä ±â¾÷ÀÇ Áö¸®Àû È®´ë, À¯¸®ÇÑ ±ÔÁ¦ ¿ä°Ç µîÀÇ ¿äÀÎÀ¸·Î 2022³â ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿¹Ãø ±â°£ µ¿¾È Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ°ÍÀº °Ç°ÇÑ ¶óÀÌÇÁ ½ºÅ¸ÀÏÀ» Àå·ÁÇÏ´Â Á¤ºÎÀÇ À̴ϼÅƼºê°¡ Áõ°¡ÇÏ°í Àֱ⠶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ ÀÌ Áö¿ª¿¡¼´Â ¿Ã¶õÀÚÇÉ ÀǾàÇ°À» ÆǸÅÇÏ´Â ¾àÁ¡À̳ª ¼Ò¸Å ¾à±¹ÀÌ Áõ°¡ÇÏ°í ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÏ°í ÀÖ½À´Ï´Ù.
º» ¿¬±¸ÀÇ ¸ñÀûÀº ÃÖ±Ù ¸î ³âµ¿¾È ´Ù¾çÇÑ ºÎ¹® ¹× ±¹°¡ ½ÃÀå ±Ô¸ð¸¦ ¹àÈ÷°í ¾ÕÀ¸·Î ¼ö³â°£ ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ º¸°í¼´Â Á¶»ç ´ë»ó ±¹°¡ÀÇ »ê¾÷ÀÇ ÁúÀû ¹× ¾çÀû Ãø¸éÀ» Æ÷ÇÔÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù.
¶ÇÇÑ ½ÃÀåÀÇ ¹Ì·¡ ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃËÁø¿äÀÎ ¹× °úÁ¦ µî Áß¿äÇÑ Ãø¸é¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ Á¤º¸µµ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ±â¾÷ÀÇ °æÀï ±¸µµ ¹× Á¦Ç° Á¦°ø¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚ°¡ ÅõÀÚÇÒ ¼ö ÀÖ´Â ¸¶ÀÌÅ©·Î ½ÃÀåÀÇ ÀáÀçÀûÀÎ ±âȸµµ Æ÷ÇÔÇÏ°í ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
Á¦2Àå ¼¼°èÀÇ ¿Ã¶õÀÚÇÉ ½ÃÀå Á¤ÀÇ ¹× ¹üÀ§
- Á¶»ç ¸ñÀû
- ½ÃÀå Á¤ÀÇ ¹× ¹üÀ§
- Á¶»ç ´ë»ó³âµµ
- ȯÀ² º¯È¯À²
Á¦3Àå ¼¼°èÀÇ ¿Ã¶õÀÚÇÉ ½ÃÀå ¿ªÇÐ
- ¿Ã¶õÀÚÇÉ ½ÃÀåÀÇ ¿µÇ⠺м®(2020-2030³â)
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
- ¼¼°è Á¤½ÅºÐ¿Áõ À¯º´·ü »ó½Â
- Á¤½ÅÁúȯ¿¡ ´ëÇÑ Á¤ºÎ ´ëóÀÇ ±ÞÁõ
- Á¤½ÅÁúȯ¿¡ ´ëÇÑ ¼ÒºñÀÚ ÀǽÄÀÇ °íÁ¶
- ½ÃÀåÀÇ °úÁ¦
- ¿Ã¶õÀÚÇÉÀÇ °íºñ¿ë
- Á¦Á¦¿¡ ÀÇÇÑ ºÎÀÛ¿ë
- ½ÃÀå ±âȸ
- ¿Ã¶õÀÚÇÉ Á¦Á¦ÀÇ Áøº¸
- Á¤½ÅÁúȯ Áõ°¡
Á¦4Àå ¼¼°èÀÇ ¿Ã¶õÀÚÇÉ ½ÃÀå »ê¾÷ ºÐ¼®
- Porter's Five Forces ¸ðµ¨
- Porter's Five ForcesÀÇ ¿µÇ⠺м®
- PEST ºÐ¼®
- ÁÖ¿ä ÅõÀÚ ±âȸ
- ÁÖ¿ä ¼º°ø Àü·«
- COVID-19ÀÇ ¿µÇ⠺м®
- Æı«Àû µ¿Çâ
- ¾÷°è Àü¹®°¡ÀÇ ½ÃÁ¡
- ¾Ö³Î¸®½ºÆ®ÀÇ Á¦¾È ¹× °á·Ð
Á¦5Àå ¼¼°èÀÇ ¿Ã¶õÀÚÇÉ ½ÃÀå : ¿ëµµº°
- ½ÃÀå ÇöȲ
- ¼¼°èÀÇ ¿Ã¶õÀÚÇÉ ½ÃÀå : ¿ëµµº° ½ÇÀû ¹× ÀáÀç·Â ºÐ¼®
- ¼¼°èÀÇ ¿Ã¶õÀÚÇÉ ½ÃÀå : ¿ëµµº° ÃßÁ¤ ¹× ¿¹Ãø(2020-2030³â)
- ¿Ã¶õÀÚÇÉ ½ÃÀå : ÇÏÀ§ ºÎ¹®º° ºÐ¼®
- Á¤½ÅºÐ¿Áõ
- ¾ç±Ø¼º Àå¾Ö
- ±âŸ
Á¦6Àå ¼¼°èÀÇ ¿Ã¶õÀÚÇÉ ½ÃÀå : Åõ¿© °æ·Îº°
- ½ÃÀå ÇöȲ
- ¼¼°èÀÇ ¿Ã¶õÀÚÇÉ ½ÃÀå : Åõ¿© °æ·Îº° ½ÇÀû ¹× ÀáÀç·Â ºÐ¼®
- ¼¼°èÀÇ ¿Ã¶õÀÚÇÉ ½ÃÀå : Åõ¿© ·çÆ®º° ÃßÁ¤ ¹× ¿¹Ãø(2020-2030³â)
- ¿Ã¶õÀÚÇÉ ½ÃÀå : ÇÏÀ§ ºÎ¹®º° ºÐ¼®
Á¦7Àå ¼¼°èÀÇ ¿Ã¶õÀÚÇÉ ½ÃÀå : À¯Åë ä³Îº°
- ½ÃÀå ÇöȲ
- ¼¼°èÀÇ ¿Ã¶õÀÚÇÉ ½ÃÀå : À¯Åë ä³Îº° ½ÇÀû ¹× ÀáÀç·Â ºÐ¼®
- ¼¼°èÀÇ ¿Ã¶õÀÚÇÉ ½ÃÀå : À¯Åë ä³Îº° ÃßÁ¤ ¹× ¿¹Ãø(2020-2030³â)
- ¿Ã¶õÀÚÇÉ ½ÃÀå : ÇÏÀ§ ºÎ¹® ºÐ¼®
- º´¿ø ¾à±¹
- ¾à±¹ ¹× ¼Ò¸Å ¾à±¹
- ¿Â¶óÀÎ Á¦°ø¾÷ü
Á¦8Àå ¼¼°èÀÇ ¿Ã¶õÀÚÇÉ ½ÃÀå : Áö¿ªº° ºÐ¼®
- ÁÖ¿ä±¹
- ÁÖ¿ä ½ÅÈï±¹
- ¿Ã¶õÀÚÇÉ ½ÃÀå : Áö¿ªº° ½ÃÀå ÇöȲ
- ºÏ¹Ì
- À¯·´
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ½ºÆäÀÎ
- ÀÌÅ»¸®¾Æ
- ±âŸ À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- Áß±¹
- Àεµ
- ÀϺ»
- È£ÁÖ
- Çѱ¹
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ³²¾ÆÇÁ¸®Ä«
- ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦9Àå °æÀï Á¤º¸
- ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®
- ÁÖ¿ä ½ÃÀå Àü·«
- ±â¾÷ ÇÁ·ÎÆÄÀÏ
- Bristol-Myers Squibb Company
- ÁÖ¿ä Á¤º¸
- °³¿ä
- À繫(µ¥ÀÌÅÍÀÇ ÀÌ¿ë°¡´É¼º¿¡ µû¸§)
- Á¦Ç° °³¿ä
- ÃÖ±Ù µ¿Çâ
- Dr. Reddy's Laboratories Ltd
- Endo International plc
- Teva Pharmaceutical Industries Ltd
- Sun Pharmaceutical Industries Ltd
- Mylan NV
- Novartis AG
- Lupin Ltd.
- Cipla Inc
- Eli Lily and Company
- Research Process
- Á¶»ç °úÁ¤
- µ¥ÀÌÅÍ ¸¶ÀÌ´×
- ºÐ¼®
- ½ÃÀå ÃßÁ¤
- °ËÁõ
- ÃâÆÇ
- Á¶»ç ¼Ó¼º
- Á¶»çÀÇ ÀüÁ¦Á¶°Ç
AJY 24.04.02
Global Olanzapine Market is valued at approximately USD 1.84 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 2.3% during the forecast period 2023-2030. Olanzapine is a medication used to treat certain mental health conditions, primarily schizophrenia and bipolar disorder. It belongs to a class of drugs called atypical antipsychotics. Olanzapine works by affecting the levels of certain neurotransmitters in the brain, such as dopamine and serotonin. These chemicals play a role in regulating mood, thoughts, and behavior. The Olanzapine Market is expanding because of factors such as the rising prevalence of schizophrenia in various regions, the surge in government initiatives to provide facilities for mental disorders and increasing consumer awareness regarding various mental disorders.
The Olanzapine Market is growing due to an increase in the frequency of neurological illnesses and a greater demand for the treatment of acute mania in bipolar disorders. Diseases such as schizophrenia are on the rise as the world's population grows at a pace of more than 1% per year, and people aren't receiving enough neutrinos. The prevalence of emotional and mental illnesses is rising as a result of changing lifestyles and increased job and life stress, which is expected to drive lucrative growth in the Olanzapine Market. According to the National Institute of Mental Health (NIH), 52.9 million adults in the United States experienced mental illness in 2020. As a result, an increase in the number of people suffering from mental illnesses that necessitate the use of olanzapine medicine to treat the condition drives market growth. Furthermore, according to World Health Organization (WHO) data in 2022, 1 out of every 8 individuals worldwide suffers from a mental condition. Additionally, in several regions, initiatives to expand investment in new Olanzapine medications are intensifying. This initiative tends to open up new development opportunities for the Olanzapine Market. However, the high cost of olanzapine and its adverse effects hampers the expansion of the Olanzapine Market throughout the forecast period of 2023-2030.
The key regions considered for the Global Olanzapine Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the factors such as the rising prevalence of mental diseases such as schizophrenia in the region, high insurance penetration and medical facilities, geographical expansion of key players in the region and favorable regulatory requirements. Asia Pacific is expected to grow significantly over the forecast period. This is attributed to increased government efforts to encourage a healthy lifestyle. Furthermore, the increasing number of medication stores and retail pharmacies selling olanzapine pharmaceuticals in the region contributes to market growth.
Major market player included in this report are:
- Bristol-Myers Squibb Company
- Dr. Reddy's Laboratories Ltd
- Endo International plc
- Teva Pharmaceutical Industries Ltd
- Sun Pharmaceutical Industries Ltd
- Mylan N.V.
- Novartis AG
- Lupin Ltd.
- Cipla Inc
- Eli Lily and Company
Recent Developments in the Market:
- In November 2023, Royalty Pharma plc and Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd., have revealed a collaboration aimed at expediting the clinical research program for Teva's olanzapine LAI (TEV-'749). This collaboration involves a funding agreement valued at USD 125 million to cover program costs. This funding arrangement allowed company to continue to advance the development of olanzapine LAI (TEV-'749), a vital initiative for Teva Pharmaceuticals, while preserving the company's resources for more advanced and futuristic formulations.
- In October 2023, Coya Therapeutics, Inc., and Dr. Reddy's Laboratories formed an exclusive collaboration to develop and commercialize COYA 302, an investigational combination therapy for ALS.
- In April 2023, CHEPLAPHARM announced that it had reached an agreement with Eli Lilly and Company to acquire the worldwide commercial rights to Zyprexa. The deal concerns the well-established and well-positioned olanzapine/olanzapine pamoate monohydrate ("OPM") portfolio, which includes ZypAdhera / Relprevv (depot IM [2]), Zyprexa IM2 (IM), Zyprexa Zydis / Zyprexa Velotab (ODT form), and Zyprexa (oral form, tablets). This acquisition strengthens the company's portfolio in the therapeutic field of the central nervous system and marks another milestone in CHEPLAPHARM's success story.
Global Olanzapine Market Report Scope:
- Historical Data - 2020 - 2021
- Base Year for Estimation - 2022
- Forecast period - 2023-2030
- Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
- Segments Covered - Application, Route of Administration, Distribution Channel, Region
- Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
- Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Application:
- Schizophrenia
- Bipolar Disorder
- Others
By Route of Administration:
By Distribution Channel:
- Hospital Pharmacies
- Drug stores and Retail Pharmacies
- Online Providers
By Region:
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Italy
- ROE
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- RoAPAC
- Latin America
- Brazil
- Mexico
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Table of Contents
Chapter 1. Executive Summary
- 1.1. Market Snapshot
- 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
- 1.2.1. Olanzapine Market, by Region, 2020-2030 (USD Billion)
- 1.2.2. Olanzapine Market, by Application, 2020-2030 (USD Billion)
- 1.2.3. Olanzapine Market, by Route of Administration, 2020-2030 (USD Billion)
- 1.2.4. Olanzapine Market, by Distribution Channel, 2020-2030 (USD Billion)
- 1.3. Key Trends
- 1.4. Estimation Methodology
- 1.5. Research Assumption
Chapter 2. Global Olanzapine Market Definition and Scope
- 2.1. Objective of the Study
- 2.2. Market Definition & Scope
- 2.2.1. Industry Evolution
- 2.2.2. Scope of the Study
- 2.3. Years Considered for the Study
- 2.4. Currency Conversion Rates
Chapter 3. Global Olanzapine Market Dynamics
- 3.1. Olanzapine Market Impact Analysis (2020-2030)
- 3.1.1. Market Drivers
- 3.1.1.1. Rising prevalence of schizophrenia worldwide
- 3.1.1.2. Surge in government initiatives for mental disorders
- 3.1.1.3. Increasing consumer awareness regarding mental diseases
- 3.1.2. Market Challenges
- 3.1.2.1. High Cost of Olanzapine
- 3.1.2.2. Adverse effects of formulations
- 3.1.3. Market Opportunities
- 3.1.3.1. Advancements in olanzapine formulations
- 3.1.3.2. Rising mental illness
Chapter 4. Global Olanzapine Market Industry Analysis
- 4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.2. Porter's 5 Force Impact Analysis
- 4.3. PEST Analysis
- 4.3.1. Political
- 4.3.2. Economical
- 4.3.3. Social
- 4.3.4. Technological
- 4.3.5. Environmental
- 4.3.6. Legal
- 4.4. Top investment opportunity
- 4.5. Top winning strategies
- 4.6. COVID-19 Impact Analysis
- 4.7. Disruptive Trends
- 4.8. Industry Expert Perspective
- 4.9. Analyst Recommendation & Conclusion
Chapter 5. Global Olanzapine Market, by Application
- 5.1. Market Snapshot
- 5.2. Global Olanzapine Market by Application, Performance - Potential Analysis
- 5.3. Global Olanzapine Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
- 5.4. Olanzapine Market, Sub Segment Analysis
- 5.4.1. Schizophrenia
- 5.4.2. Bipolar Disorder
- 5.4.3. Others
Chapter 6. Global Olanzapine Market, by Route of Administration
- 6.1. Market Snapshot
- 6.2. Global Olanzapine Market by Route of Administration, Performance - Potential Analysis
- 6.3. Global Olanzapine Market Estimates & Forecasts by Route of Administration 2020-2030 (USD Billion)
- 6.4. Olanzapine Market, Sub Segment Analysis
- 6.4.1. Oral
- 6.4.2. Parenteral
Chapter 7. Global Olanzapine Market, by Distribution Channel
- 7.1. Market Snapshot
- 7.2. Global Olanzapine Market by Distribution Channel, Performance - Potential Analysis
- 7.3. Global Olanzapine Market Estimates & Forecasts by Distribution Channel 2020-2030 (USD Billion)
- 7.4. Olanzapine Market, Sub Segment Analysis
- 7.4.1. Hospital Pharmacies
- 7.4.2. Drug stores and Retail Pharmacies
- 7.4.3. Online Providers
Chapter 8. Global Olanzapine Market, Regional Analysis
- 8.1. Top Leading Countries
- 8.2. Top Emerging Countries
- 8.3. Olanzapine Market, Regional Market Snapshot
- 8.4. North America Olanzapine Market
- 8.4.1. U.S. Olanzapine Market
- 8.4.1.1. Application breakdown estimates & forecasts, 2020-2030
- 8.4.1.2. Route of Administration breakdown estimates & forecasts, 2020-2030
- 8.4.1.3. Distribution Channel breakdown estimates & forecasts, 2020-2030
- 8.4.2. Canada Olanzapine Market
- 8.5. Europe Olanzapine Market Snapshot
- 8.5.1. U.K. Olanzapine Market
- 8.5.2. Germany Olanzapine Market
- 8.5.3. France Olanzapine Market
- 8.5.4. Spain Olanzapine Market
- 8.5.5. Italy Olanzapine Market
- 8.5.6. Rest of Europe Olanzapine Market
- 8.6. Asia-Pacific Olanzapine Market Snapshot
- 8.6.1. China Olanzapine Market
- 8.6.2. India Olanzapine Market
- 8.6.3. Japan Olanzapine Market
- 8.6.4. Australia Olanzapine Market
- 8.6.5. South Korea Olanzapine Market
- 8.6.6. Rest of Asia Pacific Olanzapine Market
- 8.7. Latin America Olanzapine Market Snapshot
- 8.7.1. Brazil Olanzapine Market
- 8.7.2. Mexico Olanzapine Market
- 8.8. Middle East & Africa Olanzapine Market
- 8.8.1. Saudi Arabia Olanzapine Market
- 8.8.2. South Africa Olanzapine Market
- 8.8.3. Rest of Middle East & Africa Olanzapine Market
Chapter 9. Competitive Intelligence
- 9.1. Key Company SWOT Analysis
- 9.1.1. Company 1
- 9.1.2. Company 2
- 9.1.3. Company 3
- 9.2. Top Market Strategies
- 9.3. Company Profiles
- 9.3.1. Bristol-Myers Squibb Company
- 9.3.1.1. Key Information
- 9.3.1.2. Overview
- 9.3.1.3. Financial (Subject to Data Availability)
- 9.3.1.4. Product Summary
- 9.3.1.5. Recent Developments
- 9.3.2. Dr. Reddy's Laboratories Ltd
- 9.3.3. Endo International plc
- 9.3.4. Teva Pharmaceutical Industries Ltd
- 9.3.5. Sun Pharmaceutical Industries Ltd
- 9.3.6. Mylan N.V.
- 9.3.7. Novartis AG
- 9.3.8. Lupin Ltd.
- 9.3.9. Cipla Inc
- 9.3.10. Eli Lily and Company
- 9.3.11. Research Process
- 9.4. Research Process
- 9.4.1. Data Mining
- 9.4.2. Analysis
- 9.4.3. Market Estimation
- 9.4.4. Validation
- 9.4.5. Publishing
- 9.5. Research Attributes
- 9.6. Research Assumption